Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: Clinical outcomes and peripheral-blood cell recovery

Journal of Clinical Oncology

Volumn 28, Issue 7, 2010, Pages 1196-1202

  Gunturu, Krishna S ^a   Meehan, Kenneth R ^a   Mackenzie, Todd A ^a   Crocenzi, Todd S ^a   McDermott, David ^a   Usherwood, Edward J ^a   Margolin, Kim A ^a   Crosby, Nancy A ^a   Atkins, Michael B ^a   Turk, Mary Jo ^a   Ahonen, Cory ^a   Fuse, Shinichiro ^a   Clark, Joseph I ^a   Fisher, Jan L ^a   Noelle, Randolph J ^a   Ernstoff, Marc S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; RECOMBINANT INTERLEUKIN 2; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CAPILLARY LEAK SYNDROME; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL EXPANSION; CLINICAL ARTICLE; DRUG MEGADOSE; EDEMA; EFFECTOR CELL; ELECTROLYTE DISTURBANCE; FEBRILE NEUTROPENIA; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HOMEOSTASIS; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; LYMPHOCYTE; LYMPHOCYTE DEPLETION; LYMPHOCYTOPENIA; MALE; MELANOMA; MEMORY T LYMPHOCYTE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; URINE VOLUME; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; IMMUNOLOGY; METASTASIS; MIDDLE AGED;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-2; LYMPHOCYTE DEPLETION; MALE; MELANOMA; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 77949881923     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.8153     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. Ribas A, Camacho LH, Lopez-Berestein G, et al: Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23:8968-8977, 2005 (Pubitemid 46217464)
3. Hodi FS, Mihm MC, Soiffer RJ, et al: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100:4712-4717, 2003 (Pubitemid 36457795)
4. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372-8377, 2003 (Pubitemid 36842552)
5. Sanderson K, Scotland R, Lee P, et al: Autoimmunity in a phase I trial of a fully human anticytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23:741-750, 2005 (Pubitemid 46224173)
6. Korman A, Yellin M, Keler T: Tumor immunotherapy: Preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs 6:582-591, 2005 (Pubitemid 40852291)
7. Goldrath AW, Bogatzki LY, Bevan MJ: Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 192:557-564, 2000 (Pubitemid 30666256)
8. Murali-Krishna K, Ahmed R: Cutting edge: Naive T cells masquerading as memory cells. J Immunol 165:1733-1737, 2000 (Pubitemid 30643121)
9. Surh CD, Sprent J: Regulation of mature T cell homeostasis. Semin Immunol 17:183-191, 2005 (Pubitemid 40488977)
10. Hellström KE, Hellstrom I, Kant JA, et al: Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population. J Exp Med 148:799-804, 1978 (Pubitemid 9006461)
11. Maine GN, Mule JJ: Making room for T cells. J Clin Invest 110:157-159, 2002 (Pubitemid 34787351)
12. Wang LX, Kjaergaard J, Cohen PA, et al: Memory T cells originate from adoptively transferred effector and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy. J Immunol 172:3462-3468, 2004 (Pubitemid 38337926)
13. Wu Z, Bensinger SJ, Zhang J, et al: Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 10:87-92, 2004 (Pubitemid 38524703)
14. Antony PA, Piccirillo CA, Akpinarli A, et al: CD8+ T cell immunity against a tumor/self -antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174:2591-2601, 2005 (Pubitemid 40279672)
15. Reference deleted
16. Reference deleted
17. Kline J, Brown IE, Zha YY, et al: homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 14:3156-3167, 2008
18. Baecher-Allan C, Wolf E, Hafler DA: Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4+CD25+ T cells. Clin Immunol 115:10-18, 2005
19. Chang CC, Ciubotariu R, Manavalan JS, et al: Tolerization of dendritic cells by TS cells: The crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 3:237-243, 2002 (Pubitemid 34218114)
20. Letsch A, Keilholz U, Schadendorf D, et al: High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma. Int J Cancer 87:659-664, 2000 (Pubitemid 30620408)
21. Hu HM, Poehlein CH, Urba WJ, et al: Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 62:3914-3919, 2002 (Pubitemid 34791051)
22. Atkins MB, Lotze MT, Dutcher JP, et al: High dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116, 1999